末梢動脈疾患（PAD）：市場洞察・競合環境・市場予測 (～2030年)

末梢動脈疾患 (PAD) の市場規模は、2023年の37億5,764万米ドルから、予測期間中はCAGR 6.64％で推移し、2030年には54億6,902万米ドルの規模に成長すると予測されています。

末梢動脈疾患 (PAD) 治療の需要は、主にPADや動脈硬化の有病率の上昇、肥満、糖尿病、高血圧の有病率の上昇、高齢者人口の負担増、低侵襲手技の需要増などに起因して、予測期間中に押し上げられると予測されています。

末梢動脈疾患 (PAD)：市場力学

PAD市場の成長促進要因の1つは、動脈硬化につながるPADの有病率の上昇です。American Heart Associationのデータ (2023年) によると、世界平均で約2億人がPADを患っています。また、Global Burden of Disease (2019年) によると、2019年の40～70歳のPAD患者数は世界で5,640万人を示しています。

治療タイプ別では、デバイス部門の血管形成術用バルーンが2023年に大きな収益シェアを示しています。

血管形成術用バルーンは、沈着が診断された動脈にカテーテルに取り付けられたバルーンを挿入します。血管形成術用バルーンカテーテルは、沈着または閉塞部位まで慎重かつ正確に動脈内を誘導され、その後膨張して開口部を広げ、プラークの沈着を動脈の壁に押し付けます。これにより、閉塞した動脈の血流が回復し、体内の筋肉や組織に酸素の豊富な血液が送られるようになります。血管形成術用バルーンの大きな利点は、低侵襲で末梢動脈疾患の治療ができることです。血管形成術用バルーンカテーテルを使用した末梢動脈疾患の治療では、患者は合併症や制限をあまり受けることなく、処置後すぐに日常生活に戻ることができます。

地域別では、北米が2023年の市場で最も高いシェアを示す見通しです。これは、末梢動脈疾患の効果的な治療に関する認識を高めるための政府の取り組みが増加していること、高齢者患者の負担が増加していること、肥満、高血圧、糖尿病の有病率が増加していること、高度な医療施設がこの地域に存在することなどに起因しています。

当レポートでは、世界の末梢動脈疾患 (PAD) の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 末梢動脈疾患 (PAD) 市場レポート：イントロダクション

• 調査範囲
• 市場の分類
• 市場の想定

第2章 末梢動脈疾患 (PAD) 市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 末梢動脈疾患 (PAD) 市場：主要要因分析

• 市場促進要因
  • 末梢動脈疾患および動脈硬化症の罹患率の上昇
  • 肥満、糖尿病、高血圧の増加
  • 高齢化による負担の増大
  • 低侵襲手術の需要の増加
• 市場抑制要因と課題
  • さまざまなデバイスの高コスト
  • さまざまな治療に関連する有害事象
• 市場機会
  • 技術の進歩と治療用PAD機器の採用増加

第6章 末梢動脈疾患 (PAD) 市場：ポーターのファイブフォース分析

第7章 末梢動脈疾患 (PAD) 市場の評価

• 治療タイプ別
  • デバイス
  • 薬物
• エンドユーザー別
  • 病院
  • 外来手術センター
  • 専門クリニック
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 末梢動脈疾患 (PAD) 市場：企業・製品プロファイル

• Medtronic
• Koninklijke Philips N.V.
• B. Braun SE
• Boston Scientific Corporation
• BD
• Terumo Corporation
• Biotronik
• Cordis
• Abbott
• AngioDynamics
• Cardiovascular Systems, Inc.
• Bluesail Medical Co., Ltd.
• Contego Medical, Inc.
• Argon Medical
• REX Medical
• Merck & Co., Inc.
• Sanofi
• Johnson and Johnson Services, Inc.
• Otivio
• Reflow Medical Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Peripheral Artery Disease (PAD) Market in Global (2021-2030)
• Table 3: Peripheral Artery Disease (PAD) Market in Global by Treatment Type (2021-2030)
• Table 4: Peripheral Artery Disease (PAD) Market in Global by End-User (2021-2030)
• Table 5: Peripheral Artery Disease (PAD) Market in Global by Geography (2021-2030)
• Table 6: Peripheral Artery Disease (PAD) Market in North America (2021-2030)
• Table 7: Peripheral Artery Disease (PAD) Market in the United States (2021-2030)
• Table 8: Peripheral Artery Disease (PAD) Market in Canada (2021-2030)
• Table 9: Peripheral Artery Disease (PAD) Market in Mexico (2021-2030)
• Table 10: Peripheral Artery Disease (PAD) Market in Europe (2021-2030)
• Table 11: Peripheral Artery Disease (PAD) Market in France (2021-2030)
• Table 12: Peripheral Artery Disease (PAD) Market in Germany (2021-2030)
• Table 13: Peripheral Artery Disease (PAD) Market in United Kingdom (2021-2030)
• Table 14: Peripheral Artery Disease (PAD) Market in Italy (2021-2030)
• Table 15: Peripheral Artery Disease (PAD) Market in Spain (2021-2030)
• Table 16: Peripheral Artery Disease (PAD) Market in the Rest of Europe (2021-2030)
• Table 17: Peripheral Artery Disease (PAD) Market in Asia-Pacific (2021-2030)
• Table 18: Peripheral Artery Disease (PAD) Market in China (2021-2030)
• Table 19: Peripheral Artery Disease (PAD) Market in Japan (2021-2030)
• Table 20: Peripheral Artery Disease (PAD) Market in India (2021-2030)
• Table 21: Peripheral Artery Disease (PAD) Market in Australia (2021-2030)
• Table 22: Peripheral Artery Disease (PAD) Market in South Korea (2021-2030)
• Table 23: Peripheral Artery Disease (PAD) Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Peripheral Artery Disease (PAD) Market in the Rest of the World (2021-2030)
• Table 25: Peripheral Artery Disease (PAD) Market in the Middle East (2021-2030)
• Table 26: Peripheral Artery Disease (PAD) Market in Africa (2021-2030)
• Table 27: Peripheral Artery Disease (PAD) Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Peripheral Artery Disease (PAD) Market in Global (2021-2030)
• Figure 3: Peripheral Artery Disease (PAD) Market in Global by Treatment Type (2021-2030)
• Figure 4: Peripheral Artery Disease (PAD) Market in Global by End-User (2021-2030)
• Figure 5: Peripheral Artery Disease (PAD) Market in Global by Geography (2021-2030)
• Figure 6: Peripheral Artery Disease (PAD) Market in North America (2021-2030)
• Figure 7: Peripheral Artery Disease (PAD) Market in the United States (2021-2030)
• Figure 8: Peripheral Artery Disease (PAD) Market in Canada (2021-2030)
• Figure 9: Peripheral Artery Disease (PAD) Market in Mexico (2021-2030)
• Figure 10: Peripheral Artery Disease (PAD) Market in Europe (2021-2030)
• Figure 11: Peripheral Artery Disease (PAD) Market in France (2021-2030)
• Figure 12: Peripheral Artery Disease (PAD) Market in Germany (2021-2030)
• Figure 13: Peripheral Artery Disease (PAD) Market in United Kingdom (2021-2030)
• Figure 14: Peripheral Artery Disease (PAD) Market in Italy (2021-2030)
• Figure 15: Peripheral Artery Disease (PAD) Market in Spain (2021-2030)
• Figure 16: Peripheral Artery Disease (PAD) Market in the Rest of Europe (2021-2030)
• Figure 17: Peripheral Artery Disease (PAD) Market in Asia-Pacific (2021-2030)
• Figure 18: Peripheral Artery Disease (PAD) Market in China (2021-2030)
• Figure 19: Peripheral Artery Disease (PAD) Market in Japan (2021-2030)
• Figure 20: Peripheral Artery Disease (PAD) Market in India (2021-2030)
• Figure 21: Peripheral Artery Disease (PAD) Market in Australia (2021-2030)
• Figure 22: Peripheral Artery Disease (PAD) Market in South Korea (2021-2030)
• Figure 23: Peripheral Artery Disease (PAD) Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Peripheral Artery Disease (PAD) Market in the Rest of the World (2021-2030)
• Figure 25: Peripheral Artery Disease (PAD) Market in the Middle East (2021-2030)
• Figure 26: Peripheral Artery Disease (PAD) Market in Africa (2021-2030)
• Figure 27: Peripheral Artery Disease (PAD) Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Peripheral Artery Disease (PAD) market by Treatment Type (Devices [Angioplasty Balloons, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Guidewires], and Drugs), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increase in the prevalence and burden of PAD & arteriosclerosis and escalating burden of the geriatric population globally

The peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030. The demand for Peripheral Artery Disease (PAD) is primarily being boosted owing to the rising prevalence of peripheral artery disease & arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, the rising demand for minimally invasive procedures, among others during the forecast period from 2024 to 2030.

Peripheral Artery Disease (PAD) Market Dynamics:

One of the main drivers for the growth of the peripheral artery disease (PAD) market is the rising prevalence of PAD disease leading to arteriosclerosis. As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

As per the Canadian Journal of Cardiology article (2022), the global prevalence of peripheral artery disease (PAD) was 5.6% in 2021, with higher prevalence estimates in high-income countries than in low-income countries.

Based on a recent research study, it had been reported that 75% of acute myocardial infarctions globally occurred from plaque rupture and the highest incidence of plaque rupture was observed in men above 45 years; whereas, in women, the incidence increased beyond age 50 years. PAD prevalence is similar or higher in women compared with men mainly because women form the major section of the elderly population.

Therefore, the factors stated above collectively will drive the overall Peripheral Artery Disease (PAD) market during the forecast period from 2024 to 2030.

However, the high cost of different devices, adverse events related to various treatments and others may limit their end-user base, thus acting as key constraints limiting the growth of the Peripheral Artery Disease (PAD).

Peripheral Artery Disease (PAD) Market Segment Analysis:

Peripheral Artery Disease (PAD) market by Treatment Type (Devices [Angioplasty Balloons, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Guidewires], and Drugs), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment type segment of the Peripheral Artery Disease (PAD) market, the angioplasty balloons in the devices category is estimated to amass a significant revenue share in the Peripheral Artery Disease (PAD) market in 2023. This can be attributed to the various properties, technical advantages, and increasing product development activities such as collaborations and regulatory approvals of angioplasty balloons during the forecast period.

Angioplasty balloon involves the insertion of a balloon attached to a catheter into an artery where the deposition has been diagnosed. The angioplasty balloon catheter is guided carefully and accurately through the artery to the deposition or blockage site and then inflated to widen the opening which pushes the plaque deposition against the wall of the artery. This allows for blood flow restoration in a blocked artery and elevation in the delivery of oxygen-rich blood to the muscles and tissues in the body. The major advantage of an angioplasty balloon is that it allows for the treatment of peripheral artery disease in a minimally invasive manner. Treatment of peripheral artery disease with the utilization of angioplasty balloon catheter ensures that the patient can return to day-to-day activities shortly after the procedure without much complications and restrictions.

The increasing technological advancements such as use of Drug-Coated Balloon (DCB) angioplasty in the treatment of PAD is going to play a crucial role in the peripheral artery disease market. In DCB, balloon coated with anti-proliferative medication and a carrier molecule (or excipient) is delivered to narrowed or blocked artery for treatment of PAD.

For example, Chocolate Touch(R) developed by TriReme Medical LLC is next generation drug-coated angioplasty balloon for the treatment of patients suffering from peripheral artery disease in the superficial femoral artery and the popliteal artery. Chocolate Touch(R) Drug-coated Balloon PTA Catheter received the US FDA approval in November 2022.

Hence, owing to all the aforementioned factors, the market will experience an increased demand for angioplasty balloons thus driving the devices category growth in the peripheral artery disease market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall peripheral artery disease (PAD) market:

Among all the regions, North America is expected to account for the highest proportion of the peripheral artery disease (PAD) Market in 2023, out of all regions. This is owing to the growing government initiatives to raise awareness regarding effective treatment of peripheral artery diseases, rising burden of elderly patients, increasing prevalence of obesity, hypertension, and diabetes, and the presence of an advanced healthcare facilities in the region, thus boosting the peripheral artery disease market in North America.

As per data by the American Heart Association, 2021, PAD affected about 8.5 million U.S. adults over the age of 40, in 2021. As per the same source, African Americans are more likely to screen positive for PAD than non-Hispanic adults.

Also, according to data provided by Statistic Canada, PAD is widely prevalent in the country, affecting approximately 800,000 Canadians, every year.

The increasing prevalence of people with obesity and overweight will increase the market for peripheral artery disease as obese patients are 3-5 times more likely to develop the most severe complication of PAD. The Centers for Disease Control and Prevention (CDC) stated that in 2019, all US states and territories had an obesity rate of at least 20%, in 2019. Also as per the Government of Canada, about 1 in 4 Canadian adults are living with obesity on an average annually. Obesity rates among Canadian adults are higher in men as compared to women. The obese patients are 3-5 times more likely to develop the most severe complication of PAD called critical limb ischemia.

Furthermore in June 2022, Cardio Flow, Inc., received the U.S. Food and Drug Administration (FDA) clearance for the company's FreedomFlow(R) Peripheral Guidewire.

Additionally, in May 2022, Medtronic announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the Peripheral Artery Disease (PAD) market.

Peripheral Artery Disease (PAD) Market key players:

Some of the key market players operating in the peripheral artery disease (PAD) market include Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

Recent Developmental Activities in the Peripheral Artery Disease (PAD) Market:

• In March 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which assessed the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD).
• In October 2023, Cardio Flow, Inc., a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow Orbital Atherectomy Peripheral Platform.
• In June 2023, Endologix announced that it received FDA approval for its Detour system to treat long, complex superficial femoropopliteal lesions. It treats complex peripheral artery disease by allowing physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg.

Key Takeaways from the Peripheral Artery Disease (PAD) Market Report Study

• Market size analysis for current Peripheral Artery Disease (PAD) market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the Peripheral Artery Disease (PAD) market
• Various opportunities available for the other competitors in the Peripheral Artery Disease (PAD) market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Peripheral Artery Disease (PAD) market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Peripheral Artery Disease (PAD) market growth in the coming future?

Target audience who can be benefited from this Peripheral Artery Disease (PAD) Market Report Study

• Peripheral Artery Disease (PAD) product providers
• Research organizations and consulting companies
• Peripheral Artery Disease (PAD)-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Peripheral Artery Disease (PAD)
• Various end-users who want to know more about the Peripheral Artery Disease (PAD) market and the latest developments in the Peripheral Artery Disease (PAD) market

Frequently Asked Questions for the Peripheral Artery Disease (PAD) Market:

1. What are Peripheral Artery Disease (PAD)?

• The peripheral artery disease (PAD) is a common cardiovascular condition that is caused by plaque build-up in the arteries, resulting in restricted blood flow to the limbs. Peripheral artery disease is also linked to diabetes, aging, and high blood pressure.

2. What is the market for Peripheral Artery Disease (PAD)?

• The peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030.

3. What are the drivers for the Peripheral Artery Disease (PAD) market?

• The Peripheral Artery Disease (PAD) market is slated to witness prosperity owing to the rising prevalence of peripheral artery disease and arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, the rising demand for minimally invasive procedures, among others during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Peripheral Artery Disease (PAD) market?

• Some of the key market players operating in the peripheral artery disease (PAD) market include Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

5. Which region has the highest share in the Peripheral Artery Disease (PAD) market?

• North America is expected to dominate the overall peripheral artery disease (PAD) market during the forecast period from 2024 to 2030. This is owing to the growing government initiatives to raise awareness regarding effective treatment of peripheral artery diseases, rising burden of elderly patients, increasing prevalence of obesity, hypertension, and diabetes, and the presence of an advanced healthcare facilities in the region, thus boosting the peripheral artery disease market in North America.

Table of Contents

1. Peripheral Artery Disease (PAD) Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Peripheral Artery Disease (PAD) Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Peripheral Artery Disease (PAD) Market Key Factors Analysis

• 5.1. Peripheral Artery Disease (PAD) Market Drivers
  • 5.1.1. Rising prevalence of peripheral artery disease and arteriosclerosis
  • 5.1.2. Rising prevalence of obesity, diabetes, and high blood pressure
  • 5.1.3. Growing burden of elderly population
  • 5.1.4. Rising demand for minimally invasive procedures
• 5.2. Peripheral Artery Disease (PAD) Market Restraints and Challenges
  • 5.2.1. High cost of different devices
  • 5.2.2. Adverse events related to various treatments
• 5.3. Peripheral Artery Disease (PAD) Market Opportunities
  • 5.3.1. Technological advancements and increasing adoption of PAD devices for treatment

6. Peripheral Artery Disease (PAD) Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Peripheral Artery Disease (PAD) Market Assessment

• 7.1. By Treatment Type
  • 7.1.1. Devices
    • 7.1.1.1. Angioplasty Balloons
    • 7.1.1.2. Angioplasty Stents
    • 7.1.1.3. Plaque Modification Devices
    • 7.1.1.4. Hemodynamic Flow Alteration Devices
    • 7.1.1.5. Peripheral Guidewires
  • 7.1.2. Drugs
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Ambulatory Surgical Centres
  • 7.2.3. Specialty Clinics
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.3.3. India Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Peripheral Artery Disease (PAD) Market Size in USD million (2021-2030)

8. Peripheral Artery Disease (PAD) Market Company and Product Profiles

• 8.1. Medtronic
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Koninklijke Philips N.V.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. B. Braun SE
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Boston Scientific Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. BD
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Terumo Corporation
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Biotronik
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Cordis
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Abbott
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. AngioDynamics
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cardiovascular Systems, Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Bluesail Medical Co., Ltd.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Contego Medical, Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Argon Medical
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. REX Medical
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Merck & Co., Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Sanofi
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Johnson and Johnson Services, Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Otivio
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Reflow Medical Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us